These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18945536)

  • 1. Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L
    Eur Urol; 2009 Nov; 56(5):846-7. PubMed ID: 18945536
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Kruck S; Sievert KD
    Eur Urol; 2009 Nov; 56(5):845-6. PubMed ID: 18945542
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
    Gofrit ON
    Eur Urol; 2009 Nov; 56(5):836. PubMed ID: 18926619
    [No Abstract]   [Full Text] [Related]  

  • 5. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
    Palou J; Algaba F; Vera I; Rodriguez O; Villavicencio H; Sanchez-Carbayo M
    Eur Urol; 2009 Nov; 56(5):829-36. PubMed ID: 18926620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer].
    Masliukova EA; Pozharisskiĭ KM; Karelin MI; Startsev VIu; Ten VP
    Vopr Onkol; 2006; 52(6):643-8. PubMed ID: 17338241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival.
    Wülfing C; Eltze E; Yamini J; Wülfing P; Bierer S; Böcker W; Hertle L; Semjonow A; Sievert KD
    Eur Urol; 2005 May; 47(5):593-600. PubMed ID: 15826749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
    Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
    Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic markers for urothelial cancer: obstacles and opportunities.
    Malmström PU
    Urol Oncol; 2012; 30(4):516-7. PubMed ID: 22742563
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
    van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
    J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma.
    Fan M; Zhuang Q; Chen Y; Ding T; Yao H; Chen L; He X; Xu X
    Int J Clin Exp Pathol; 2014; 7(10):6768-75. PubMed ID: 25400757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up.
    Wülfing P; Diallo R; Kersting C; Wülfing C; Poremba C; Rody A; Greb RR; Böcker W; Kiesel L
    Clin Cancer Res; 2003 Sep; 9(11):4125-31. PubMed ID: 14519635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
    Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    Malats N; Real FX
    Eur Urol; 2009 Mar; 55(3):658. PubMed ID: 18584942
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    Burger M
    Eur Urol; 2009 Mar; 55(3):657. PubMed ID: 18584941
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.